Proton pump inhibitor-associated hypomagnesemia: What do FDA data tell us?;Hipomagnesemia asociada a inhibidores de la bomba de protones: ¿qué nos dicen los datos de la administración de alimentos y medicamentos?

Annals of Pharmacotherapy

Volumn 47, Issue 6, 2013, Pages 773-780

  Luk, Chee Phun ^a   Parsons, Richard ^a   Lee, Ya Ping ^a   Hughes, Jeffery David ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

AGE; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; HUMAN; HYPOMAGNESEMIA; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MAGNESIUM; MAGNESIUM DEFICIENCY; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84878515354     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R556     Document Type: Article

References (48)

1. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935-951.
2. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res 2009;59:135-153.
3. Mullin JM, Gabello M, Murray LJ, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today 2009;14:647-660.s
4. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep 2010;12:448-457.
5. Commonwealth Government of Australia. Drug Utilisation Subcommittee (DUSc) database. www.australianprescriber.com/magazine/34/6/artid/1063 (accessed 2012 Apr 9).
6. Lodato F, Azzaroli F, Turco L, et al. Adverse effects of proton pump inhibitors. Baillieres Best Pract Res Clin Gastroenterol 2010;24:193-201.
7. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011;56:931-950.
8. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 2012;72:437-445.
9. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010;139:1115-1127.
10. Cundy T, Mackay J. Proton pump inhibitors and severe hypomagne-saemia. Curr Opin Gastroenterol 2011;27:180-185.
11. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagne-semic hypoparathyroidism. N Engl J Med 2006;355:1834-1836.
12. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW. Omeprazole and refractory hypomagnesaemia. BMJ 2008;337:a425.
13. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol 2008;69:338-341.
14. Francois M, Levy-Bohbot N, Caron J, Durlach V. Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagne-semic hypoparathyroidism? [French] Annales d Endocrinologie 2008;69: 446-448.
15. Agarwal N, Rees A, Scanlon M. Hypomagnesaemia related to proton-pump inhibition. Endocrine Abstracts 2008;15:P24.
16. Broeren MAC, Geerdink EAM, Vader HL, van den Wall Bake AWL. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009;151:755-756. [Erratum appears in Ann Intern Med 2010; 152:268].
17. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors-a review. Neth J Med 2009;67:169-172.
18. Druce MR, Thomas JDJ, Gorrifan RJ, Kelly PA, Coppack SW, Akker SA. Hypomagnesaemia and hypocalcaemia in proton-pump inhibitors: an under-recognised phenomenon. Endocrine Abstracts 2009;16:P50.
19. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010;56:112-116.
20. Regolisti G, Cabassi A, Parenti E, Maggiore U, Fiaccadori E. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 2010;56:168-174.
21. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 2010;103:387-395.
22. Fernandez-Fernandez FJ, Sesma P, Cainzos-Romero T, Ferreira-Gonzalez L. Intermittent use of pantoprazole and famotidine in severe hypo-magnesaemia due to omeprazole. Neth J Med 2010;68:329-330.
23. Swaminathan K, Wilson J. Elusive cause of hypomagnesaemia. BMJ 2011;343:d5087.
24. Arulanantham N, Anderson M, Gittoes N, Ferner RE. A 63-year-old man with hypomagnesaemia and seizures. Clin Med 2011;11:591-593.
25. Furlanetto TW, Faulhaber GAM. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 2011;171:1391-1392.
26. Quasdorff M, Mertens J, Dinter J, Steffen H-M. Recurrent hypomagne-semia with proton-pump inhibitor rechallenge. Ann Intern Med 2011; 155:405-407.
27. Ayuk J, Gittoes NJL. How should hypomagnesaemia be investigated and treated? Clin Endocrinol 2011;75:743-746.
28. Negri AL, Valle EED. Hypomagnesaemia/hypokalemia associated with the use of esomeprazole. Curr Drug Saf 2011;6:204-206.
29. Cano Megías M, Álvarez Santirso R, Iglesias Lozano P, Carrasco De La Fuente M, Pérez López G. Hypomagnesemia induced by proton pump inhibitors, diarrhea, and lactose intolerance. Endocrinol Nutr 2011;58:550-554.
30. Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007;102:2648-2654.
31. Hmu C, Moulik P, Macleod A. Severe hypomagnesaemia due to lanso-prazole. BMJ Case Rep 2009. doi: 10.1136/bcr.07.2009.2098
32. Matsuyama J, Tsuji K, Doyama H, et al. Hypomagnesemia associated with a proton pump inhibitor. Intern Med 2012;51:2231-2234.
33. Martinez Faedo C, Bellido Castaneda V, Riestra Fernandez M. [Severe hypomagnesemia refractory to oral supplementation associated to omeprazole treatment]. Endocrinol Nutr 2012;59:463-465.
34. Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012;46:93-114.
35. Sumukadas D, McMurdo MET, Habicht D. Proton pump inhibitors are associated with lower magnesium levels in older people with chronic kidney disease. J Am Geriatr Soc 2012;60:392-393.
36. Gau JT, Yang YX, Chen R, Kao TC. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf 2012;21:553-559.
37. Food and Drug Administration. FDA drug associated with long-term use of proton pump inhibitor drugs. www.fda/gov/Drugs/DrugSafety/ucm245011.htm (accessed 2012 Apr 9).
38. Therapeutic Goods Administration. Medicines safety update. www.tga.gov.au/hp/msu-2011-03.htm (accessed 2012 Apr 9).
39. Lameris AL, Monnens LA, Bindels RJ, Hoenderop JGJ. Drug-induced alterations in Mg2+ homoeostasis. Clin Sci (Colch) 2012;123:1-14.
40. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esome -prazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-2620.
41. Kroenke K, Spitzer RL. Gender differences in the reporting of physical and somatoform symptoms. Psychosom Med 1998;60:150-155.
42. George CJ, Korc B, Ross JS. Appropriate proton pump inhibitor use among older adults: a retrospective chart review. Am J Geriatr Pharmacother 2008;6:249-254.
43. Wu J, Carter A. Abnormal laboratory results. Magnesium: the forgotten electrolyte. Aust Prescr 2007;30:102-105.
44. Gums J. Magnesium in cardiovascular and other disorders. Am J Health Syst Pharm 2004;61:1569-1576.
45. Maeda Y, Kojima N, Araki Y, Uno T, Nishigaki K, Inaba N. Does a proton pump inhibitor cause hypokalemia? Intern Med 2011;50:1045-1050.
46. Evenepoel P. Alteration in digestion and absorption of nutrients during profound acid suppression. Baillieres Best Pract Res Clin Gastroenterol 2001;15:539-551.
47. Thongon N, Krishnamra N. Omeprazole decreases magnesium transport across Caco-2 monolayers. World J Gastroenterol 2011;17:1574-1583.
48. Mullin JM, Valenzano MC, Whitby M, et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther 2008;28:1317-1325.